

Lonhala[™] Magnair[™] (glycopyrrolate) – New drug approval

- On December 5, 2017, <u>Sunovion announced</u> the FDA approval of <u>Lonhala Magnair (glycopyrrolate)</u>, for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- COPD is a common, preventable and treatable disease that is characterized by persistent
 respiratory symptoms and airflow limitation. Symptoms of COPD include coughing, wheezing,
 shortness of breath, excess production of mucus in the lungs, the inability to breathe deeply and the
 feeling of being unable to breathe. Approximately 15.7 million adults in the U.S. have COPD.
- Lonhala Magnair is a long-acting muscarinic antagonist (LAMA) bronchodilator that helps the
 muscles around the airways in the lungs stay relaxed to prevent COPD symptoms. Lonhala Magnair
 is the first nebulized LAMA approved for COPD.
- The safety and efficacy of Lonhala Magnair were demonstrated in two 12-week, placebo-controlled studies (GOLDEN-3 and GOLDEN-4) enrolling 1,293 COPD patients and a 48-week, open-label, active-controlled study (GOLDEN-5) of 1,087 COPD patients. For the placebo-controlled studies, the primary endpoint was the change from baseline in trough forced expiratory volume in one second (FEV₁) at day 84 vs. placebo.
 - In GOLDEN-3, the change in FEV₁ was 0.089 for the Lonhala Magnair-treated patients vs. 0.008 for the placebo-treated patients (difference: 0.096 [95% CI: 0.059, 0.133]).
 - In GOLDEN-4, the change in FEV₁ was 0.092 for the Lonhala Magnair-treated patients vs. 0.011 for the placebo-treated patients (difference: 0.081 [95% CI: 0.042, 0.120]).
 - In GOLDEN-5, the overall treatment emergent adverse events incidences were similar for the Lonhala Magnair and <u>Spiriva[®] HandiHaler[®] (tiotropium)</u> groups over 48 weeks.
- Warnings and precautions of Lonhala Magnair include deterioration of disease and acute episodes, paradoxical bronchospasm, immediate hypersensitivity reactions, worsening of narrow-angle glaucoma, and worsening of urinary retention.
- The most common adverse reactions (≥ 2% and higher than placebo) with Lonhala Magnair use were dyspnea and urinary tract infection.
- The recommended dose of Lonhala Magnair is the inhalation of the contents of one Lonhala vial twice-daily (1 vial in the morning and 1 vial in the evening) using Magnair.
- Sunovion plans to launch Lonhala Magnair in early 2018. Lonhala Magnair will be available as an
 aqueous solution for inhalation in a unit-dose, single-use 1 mL vial containing 25 mcg of
 glycopyrrolate.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.